Table 1.
Cost-effectiveness of quadrivalent influenza vaccination (QIV) compared to trivalent vaccine (TIV): base case scenario with lifetime horizon.
| TIV | QIV | Difference | |
|---|---|---|---|
| Spanish Healthcare System costs | 11,901,394,637 € | 12,348,949,428 € | 447,554,791 € |
| Societal costs | 34,462,064,137 € | 34,364,483,970 € | − 97,580,167 € |
| Total costs | 46,363,458,774 € | 46,713,433,398 € | 349,974,624 € |
| Life years | 1,143,182,206 | 1,143,233,538 | 51,332 |
| QALYs |
1,038,585,055 |
1,038,625,059 |
40,005 |
| ICER (€/QALY) NHS perspective | 11,188 € | ||
| ICER (€/QALY) Societal perspective | 8,748 € |
TIV: Trivalent influenza vaccine; QIV: Quadrivalent influenza vaccine; QALY: Quality-adjusted life year; ICER: Incremental cost-effectiveness ratio; NHS: National Health System.